Initial Stroke Analysis

Group 29: Helena Møller, Emma Christiansen, Casper Harreby, Frederik Holmstrup, and Laura Christiansen

Introduction

The International Stroke Trial v. 2 data

  • Assessing efficacy and safety of antithrombotic therapy compared to control.
  • Antithrombotic agents: Aspirin and subcutaneous Heparin.

Ischaemic stroke and treatments

  • Ischaemic stroke: Medical condition in which poor blood flow to a part of the brain causes cell death

Project Aim

  • Assessing effects of antithrombotics (heparin and aspirin) for recurrent ischaemic strokes

Methods

Raw data:

  • 19435 observations with 112 variables.

01_load:

  • Data has been loaded and saved in a tsv-file.

02_clean:

  • Global syntax of NA, and Y/N for binary variables.
  • Global syntax for the use of numbers 1-8 as to describe causes of death.
  • Correction of errors made when the data was collected.
  • Removal of column determined to be irrelevant.
  • Merging of columns for easier data analysis.
  • Data was split and re-joined into one.

03_augment

  • Groups created based on different treatments, and different doses of aspirin and heparin.

Descriptive analysis

  • Observations/patients: 19,435
  • Variables: 98
  • Treatment groups: 6

Data visualization: Events during first 14 days

  • Patients receiving higher heparin doses and asprin are more frequent in cerebral bleed/haemorrhagic stroke group
  • Likewise, higher heparin doses and aspirin patients are more represented in patients with indicator of non-cerebral bleed
  • Patient group receiving no trial medication had more subjects with indicator of pulmonary embolism

Data visualization: type of stroke

Data visualization: effects of treatments

R for Bio Data Science